![1985R3821 — LV — 01.11.2014 — 018.001 Šis dokuments ir izveidots vienīgi dokumentācijas nolūkos, un iestādes neuzņemas nekādu atbildību par tā saturu B PADOMES REGULA (EEK) Nr. 3821/85 (1985. gada 20. decembris) par reģistrācijas ... 1985R3821 — LV — 01.11.2014 — 018.001 Šis dokuments ir izveidots vienīgi dokumentācijas nolūkos, un iestādes neuzņemas nekādu atbildību par tā saturu B PADOMES REGULA (EEK) Nr. 3821/85 (1985. gada 20. decembris) par reģistrācijas ...](https://eur-lex.europa.eu/resource.html?uri=celex:01985R3821-20141101.LAV.xhtml.L_2002207LV.01012401.tif.jpg)
1985R3821 — LV — 01.11.2014 — 018.001 Šis dokuments ir izveidots vienīgi dokumentācijas nolūkos, un iestādes neuzņemas nekādu atbildību par tā saturu B PADOMES REGULA (EEK) Nr. 3821/85 (1985. gada 20. decembris) par reģistrācijas ...
18.pielikums Ministru kabineta 2006.gada 19.decembra noteikumiem Nr.1046 Veselības aprūpes pakalpojumu tarifi par profilakse
by Submitted in partial satisfaction of the requirements for degree of in in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORN
18.pielikums Ministru kabineta 2006.gada 19.decembra noteikumiem Nr.1046 Veselības aprūpes pakalpojumu tarifi par profilakses,
by Submitted in partial satisfaction of the requirements for degree of in in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORN
Veselības ministrijas iesniegtajā redakcijā 18.pielikums Ministru kabineta 2006.gada 19.decembra noteikumiem Nr.1046
![Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy | Acta Neuropathologica Communications | Full Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy | Acta Neuropathologica Communications | Full](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40478-019-0774-7/MediaObjects/40478_2019_774_Fig2_HTML.png)
Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy | Acta Neuropathologica Communications | Full
![Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy | Acta Neuropathologica Communications | Full Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy | Acta Neuropathologica Communications | Full](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40478-019-0774-7/MediaObjects/40478_2019_774_Fig4_HTML.png)
Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy | Acta Neuropathologica Communications | Full
![Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy | Acta Neuropathologica Communications | Full Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy | Acta Neuropathologica Communications | Full](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40478-019-0774-7/MediaObjects/40478_2019_774_Fig1_HTML.png)